{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:19Z","timestamp":1778711839235,"version":"3.51.4"},"reference-count":23,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It has been unclear whether regimens containing topotecan + ara-C (TA) or fludarabine + ara-C (FA) \u00b1 idarubicin are superior to regimens containing idarubicin + ara-C (IA) without either fludarabine or topotecan for treatment of newly diagnosed acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t), or RAEB. Of 1279 patients treated here for these diagnoses between 1991 and 1999, 322 received IA regimens, 600 FA regimens, and 357 TA regimens. All regimens used ara-C doses of 1 to 2 gm\/m2\/d, given by continuous infusion in IA, and over 2 to 4 hours in FA and TA. Complete remission (CR) rates were lower with FA (55%) and TA (59%) than with IA (77%). Both event-free survival (EFS) in CR and survival were shorter: median EFS in CR (95% confidence interval) was 63 weeks (range, 55-76 weeks) for IA, 40 (range, 31-46 weeks) for FA, and 36 (range, 27-44 weeks) for TA; median survival was 77 weeks (range, 57-88 weeks) for IA, 30 (range, 27-35 weeks) for FA, and 41 (range, 35-50 weeks) for TA. These trials were not randomized, and patients with worse prognoses were disproportionately given the FA and TA regimens. Nonetheless, after accounting for prognosis the FA and TA regimens remained highly significantly associated with lower CR rates, shorter EFS in CR, and shorter survival. Accounting for possible effects of individual trials within each of the IA, FA, and TA groups did not alter these findings. It is unlikely that, as given here, either FA or TA is, in general, superior to IA, highlighting the need for new treatments.<\/jats:p>","DOI":"10.1182\/blood.v98.13.3575","type":"journal-article","created":{"date-parts":[[2002,10,28]],"date-time":"2002-10-28T20:44:12Z","timestamp":1035837852000},"page":"3575-3583","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":124,"title":["Comparison of idarubicin + ara-C\u2013, fludarabine + ara-C\u2013, and topotecan + ara-C\u2013based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts"],"prefix":"10.1182","volume":"98","author":[{"given":"Elihu H.","family":"Estey","sequence":"first","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Thall","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry A.","family":"Pierce","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021218201421100_B1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","article-title":"Effect of diagnosis (RAEB, RAEB-t, or AML) on outcome of AML-type chemotherapy.","volume":"90","author":"Estey","year":"1997","journal-title":"Blood."},{"key":"2020021218201421100_B2","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021218201421100_B3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of arabinosyl cytosine in patients with acute myelogenous leukemia during therapy.","volume":"11","author":"Gandhi","year":"1993","journal-title":"J Clin Oncol."},{"key":"2020021218201421100_B4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199309148532","article-title":"Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia.","volume":"9","author":"Estey","year":"1993","journal-title":"Leuk Lymphoma."},{"issue":"11","key":"2020021218201421100_B5","first-page":"504a","article-title":"Routine use of fludarabine- or topotecan-containing chemotherapy is not indicated in AML, RAEB-t, or RAEB (abstract).","volume":"96","author":"Estey","year":"2000","journal-title":"Blood."},{"key":"2020021218201421100_B6","first-page":"1","article-title":"Idarubicin plus continuous-infusion high-dose cytosine arabinoside as treatment for patients with acute myeloid leukemia or myelodysplastic syndrome.","volume":"20(suppl 8)","author":"Estey","year":"1993","journal-title":"Semin Oncol."},{"key":"2020021218201421100_B7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.leu.2401443","article-title":"Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy.","volume":"13","author":"Estey","year":"1999","journal-title":"Leukemia."},{"key":"2020021218201421100_B8","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +\/- all-trans retinoic acid and\/or granulocyte-colony stimulating factor in poor prognosis newly-diagnosed non-APL AML and MDS.","volume":"93","author":"Estey","year":"1999","journal-title":"Blood."},{"key":"2020021218201421100_B9"},{"key":"2020021218201421100_B10","first-page":"459a","article-title":"Lisofylline reduces infection rate and improves survival in patients undergoing allogeneic bone marrow transplantation: results of a randomized placebo-controlled trial (abstract).","volume":"88(suppl 1)","author":"List","year":"1996","journal-title":"Blood."},{"key":"2020021218201421100_B11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimator from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2020021218201421100_B12","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration.","volume":"60","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"2020021218201421100_B13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B."},{"key":"2020021218201421100_B14","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data.","author":"Therneau","year":"2000"},{"key":"2020021218201421100_B15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals.","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika."},{"key":"2020021218201421100_B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3121-7","volume-title":"Modern Applied Statistics With Splus","author":"Venables","year":"1999","edition":"3rd ed."},{"key":"2020021218201421100_B17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally-weighted regression and smoothing scatterplots.","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc."},{"key":"2020021218201421100_B18","volume-title":"The New S Language.","author":"Becker","year":"1988"},{"key":"2020021218201421100_B19","volume-title":"A package for survival analysis in S.","author":"Therneau","year":"1994"},{"key":"2020021218201421100_B20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","article-title":"Use of G-CSF before, during, and after fludarabine + ara-C induction therapy of newly-diagnosed AML or MDS: comparison with fludarabine + ara-C without G-CSF.","volume":"12","author":"Estey","year":"1994","journal-title":"J Clin Oncol."},{"key":"2020021218201421100_B21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/1097-0142(20010701)92:1<7::AID-CNCR1285>3.0.CO;2-D","article-title":"High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.","volume":"92","author":"Cortes","year":"2001","journal-title":"Cancer."},{"issue":"11","key":"2020021218201421100_B22","first-page":"327a","article-title":"Interim analysis of cytarabine and cladribine combination therapy in acute myeloid leukemia (abstract).","volume":"96","author":"Radomski","year":"2000","journal-title":"Blood."},{"key":"2020021218201421100_B23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0197-2456(93)90028-C","article-title":"The use of response-adaptive designs in clinical trials.","volume":"14","author":"Rosenberger","year":"1993","journal-title":"Control Clin Trials."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/13\/3575\/1679324\/h8240103575.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/13\/3575\/1679324\/h8240103575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:11:15Z","timestamp":1733703075000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/13\/3575\/90254\/Comparison-of-idarubicin-araC-fludarabine-araC-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,15]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2001,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.13.3575","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12,15]]}}}